scholarly journals Obsessive Compulsive and Related Disorders: From the Biological Basis to a Rational Pharmacological Treatment

2017 ◽  
Vol 21 (1) ◽  
pp. 59-62 ◽  
Author(s):  
Gabriele Sachs ◽  
Andreas Erfurth
Keyword(s):  
Pharmacological Treatment ◽  
Obsessive Compulsive ◽  
Biological Basis

Pharmacological Treatment of Obsessive-Compulsive Disorder: A Review

2001 ◽  
pp. 43-92 ◽  
Author(s):  
Joseph Zohar ◽  
Yehuda Sasson ◽  
Miriam Chopra ◽  
Daniella Amital ◽  
Iulian Iancu
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Pharmacological Treatment ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

Schizo-obsessive spectrum disorders: an update

CNS Spectrums ◽  
2016 ◽  
Vol 22 (3) ◽  
pp. 258-272 ◽  
Author(s):  
Estêvão Scotti-Muzzi ◽  
Osvaldo Luis Saide
Keyword(s):  
Dual Diagnosis ◽  
Pharmacological Treatment ◽  
Schizotypal Personality Disorder ◽  
Sufficient Evidence ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Schizotypal Personality ◽  
Spectrum Disorders ◽  
Obsessive Compulsive Disorders ◽  
Compulsive Disorders

The presence of obsessive-compulsive symptoms (OCS) and obsessive-compulsive disorders (OCD) in schizophrenia is frequent, and a new clinical entity has been proposed for those who show the dual diagnosis: the schizo-obsessive disorder. This review scrutinizes the literature across the main academic databases, and provides an update on different aspects of schizo-obsessive spectrum disorders, which include schizophrenia, schizotypal personality disorder (SPD) with OCD, OCD with poor insight, schizophrenia with OCS, and schizophrenia with OCD (schizo-obsessive disorder). An epidemiological discussion on the discrepancies observed in the prevalence of OCS and OCD in schizophrenia across time is provided, followed by an overview of the main clinical and phenomenological features of the disorder in comparison to the primary conditions under a spectral perspective. An updated and comparative analysis of the main genetic, neurobiological, neurocognitive, and pharmacological treatment aspects for the schizo-obsessive spectrum is provided, and a discussion on endophenotypic markers is introduced in order to better understand its substrate. There is sufficient evidence in the literature to demonstrate the clinical relevance of the schizo-obsessive spectrum, although little is known about the neurobiology, genetics, and neurocognitive aspects of these groups. The pharmacological treatment of these patients is still challenging, and efforts to search for possible specific endophenotypic markers would open new avenues in the knowledge of schizo-obsessive spectrum.

Obsessive-Compulsive Symptoms in Schizophrenia

2017 ◽  
Author(s):  
Michael Poyurovsky
Keyword(s):  
Longitudinal Studies ◽  
Obsessive Compulsive Disorder ◽  
Pharmacological Treatment ◽  
Patient Population ◽  
Second Generation ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Compulsive Disorder ◽  
Second Generation Antipsychotics ◽  
Psychological Studies

This chapter evidence for a relationship between obsessive-compulsive disorder and psychosis, in some patients. Obsessive-compulsive symptoms are common in individuals with schizophrenia; this ‘schizo-obsessional’ population has been relatively little studied and presents marked clinical challenges. Longitudinal studies suggest that OC symptoms precede psychosis in some patients but develop later in illness in others; they can be induced by some second-generation antipsychotics. Neurobiological and cognitive psychological studies suggest that schizo-obsessional patients have greater impairment in several domains than those with schizophrenia or OC symptoms alone. The literature on pharmacological treatment of this patient population, which is limited, is review.

Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder

2017 ◽  
Vol 31 (10) ◽  
pp. 1312-1322 ◽  
Author(s):  
Daniel L da Conceição Costa ◽  
Veronica S Barbosa ◽  
Guaraci Requena ◽  
Roseli G Shavitt ◽  
Carlos A de Bragança Pereira ◽  
...  
Keyword(s):  
Correlation Coefficient ◽  
Obsessive Compulsive Disorder ◽  
Pharmacological Treatment ◽  
Symptomatic Improvement ◽  
Severity Scale ◽  
Obsessive Compulsive ◽  
Scale Item ◽  
Compulsive Disorder ◽  
Treatment Data ◽  
And Control

We aimed to investigate which items of the Yale-Brown Obsessive-Compulsive Severity Scale best discriminate the reduction in total scores in obsessive-compulsive disorder patients after 4 and 12 weeks of pharmacological treatment. Data from 112 obsessive-compulsive disorder patients who received fluoxetine (⩽80 mg/day) for 12 weeks were included. Improvement indices were built for each Yale-Brown Obsessive-Compulsive Severity Scale item at two timeframes: from baseline to week 4 and from baseline to week 12. Indices for each item were correlated with the total scores for obsessions and compulsions and then ranked by correlation coefficient. A correlation coefficient ⩾0.7 was used to identify items that contributed significantly to reducing obsessive-compulsive disorder severity. At week 4, the distress items reached the threshold of 0.7 for improvement on the obsession and compulsion subscales although, contrary to our expectations, there was greater improvement in the control items than in the distress items. At week 12, there was greater improvement in the time, interference, and control items than in the distress items. The use of fluoxetine led first to reductions in distress and increases in control over symptoms before affecting the time spent on, and interference from, obsessions and compulsions. Resistance did not correlate with overall improvement. Understanding the pathway of improvement with pharmacological treatment in obsessive-compulsive disorder may provide clues about how to optimize the effects of medication.

Sign in / Sign up

Export Citation Format

Share Document